Figure 5

Human HLA-B*07:02 PBMCs recognize HMPV peptides. (A) Human HLA-B*07:02 PBMCs from a single donor were incubated with 10 μM HMPV peptides and recombinant human IL-2 for 7 days, IFNγ ELISPOT performed as described, and SFC expressed as average SFC/106 human PBMC in triplicate wells corrected by subtracting SFC from irrelevant peptide control wells. (B) Human HLA-B*07:02 PBMCs from 5 distinct donors were incubated with APC-labeled HMPV tetramers, enriched through a magnetic column with anti-APC beads and both depleted flowthrough unenriched (left) and enriched (right) fractions analyzed via flow cytometry.